Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
AIDS Research and Therapy|February 7, 2009
Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?Robert Horne, Colin Kovacs, Christine Katlama, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2024
Antiretrovirals and Weight Change: Weighing the EvidenceDavid Alain Wohl, John R Koethe, Paul E Sax, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
Frontiers in Immunology|November 27, 2024
Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimensNicholas T Funderburg, Susie S Y Huang, Calvin Cohen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsAndrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2026
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trialsPriscilla Y Hsue, Laura Waters, Chloe Orkin, et al.
AIDS (London, England)|February 11, 2014
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCalvin Cohen, David Wohl, Jose R Arribas, et al.
AIDS Patient Care and Stds|March 26, 2014
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysisGeorg Behrens, Bart Rijnders, Mark Nelson, et al.
Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksPaul E Sax, Edwin DeJesus, Anthony Mills, et al.
AIDS (London, England)|March 21, 2003
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyJacob P Lalezari, Joseph J Eron, Margrit Carlson, et al.
Pageof 4